Oncolytics Biotech Inc (ONCY)

$0.88 -0.09 (-9.35%)
Market Cap 104.10M
Revenue (ttm) 0.00
Net Income (ttm) -23.14M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,332,800
Avg Vol 922,268
Day's Range N/A - N/A
Shares Out 106.15M
Stochastic %K 4%
Beta 0.97
Analysts Strong Sell
Price Target $5.01

Company Profile

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoin...

Industry: Biotechnology
Sector: Healthcare
Phone: 403 670 7377
Fax: 403 283 0858
Address:
322 11th Avenue SW, Suite 804, Calgary, Canada
charlietwodogs
charlietwodogs Feb. 4 at 12:21 AM
$ONCY folks are pinning their hope on the move to nevada.. Best of luck...
0 · Reply
charlietwodogs
charlietwodogs Feb. 3 at 11:06 PM
$ONCY stupid AI BOT diamond
0 · Reply
De_man
De_man Feb. 3 at 10:31 PM
$ONCY Sp on does not matter to CF because he says it will not affect him even if the stock goes bust. On a positive not RVMD which tanked is trading at at mere 96.75 while oncy closed at .8778 , a couple decimal points off. and now we are worth once again less than 100 million but no worries as we are worth at least what the comparative stock is so we hone have to go up in value over 100 times where we are. This makes no sense except for maybe all those institutions that cf was so sure bought in maybe changed their mind and sold or no support. NO one knows what is going on but we will all keep our hopes up along with the stupid predictions. Although someone on the other board did predict a while ago, see you back at .90 and seems that they have a better track record than most. All good though, the redomicile and for sure patent extension and expected more results will all save the day....oh just one thing, we still need money.
0 · Reply
DiamondHandsHarold
DiamondHandsHarold Feb. 3 at 10:28 PM
$ONCY has real science behind it and the cancer space is starting to wake up again. Feels like one people circle back to.
0 · Reply
charlietwodogs
charlietwodogs Feb. 3 at 9:37 PM
$ONCY im sure glad price doesn't matter canadafan...
0 · Reply
charlietwodogs
charlietwodogs Feb. 3 at 9:33 PM
$ONCY where are the pumpers when we need them???🐓💩
0 · Reply
charlietwodogs
charlietwodogs Feb. 3 at 9:28 PM
$ONCY new 52 week low coming soon.
0 · Reply
aaron03
aaron03 Feb. 3 at 9:21 PM
$ONCY Clear manipulation at the end, however, I have zero confidence in Kelly as CEO. It's unfortunate. I had high hopes for him. But he's another Coffey/Thompson. Moving to Nevada doesn't do anything to the company. Getting a partnership does. And he hasn't delivered.
1 · Reply
Arrankar2099
Arrankar2099 Feb. 3 at 9:11 PM
$ONCY Notable??!
0 · Reply
AI1234
AI1234 Feb. 3 at 9:02 PM
$ONCY what a dump at the close. No manipulation here…Nothing to see here… Good grief!!! Get on with a business transaction….
0 · Reply
Latest News on ONCY
Oncolytics Biotech® Announces Results of Special Meeting of Shareholders

Jan 15, 2026, 4:01 PM EST - 19 days ago

Oncolytics Biotech® Announces Results of Special Meeting of Shareholders

Oncolytics Biotech Inc. (ONCY) Shareholder/Analyst Call Prepared Remarks Transcript

Jan 15, 2026, 11:16 AM EST - 19 days ago

Oncolytics Biotech Inc. (ONCY) Shareholder/Analyst Call Prepared Remarks Transcript

Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer

Jan 12, 2026, 9:00 AM EST - 22 days ago

Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer

Oncolytics Biotech® Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada

Jan 9, 2026, 9:00 AM EST - 25 days ago

Oncolytics Biotech® Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada

Oncolytics Biotech® Provides Update on Intellectual Property Strategy and Patent Filings

Jan 8, 2026, 9:00 AM EST - 26 days ago

Oncolytics Biotech® Provides Update on Intellectual Property Strategy and Patent Filings

Oncolytics Biotech® Expands Its Gastrointestinal Tumor Scientific Advisory Board with the Addition of Dr. Eileen O'Reilly, Dr. Neil Segal, and Dr. Van Morris

Jan 7, 2026, 9:00 AM EST - 27 days ago

Oncolytics Biotech® Expands Its Gastrointestinal Tumor Scientific Advisory Board with the Addition of Dr. Eileen O'Reilly, Dr. Neil Segal, and Dr. Van Morris

Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer

Dec 16, 2025, 9:00 AM EST - 7 weeks ago

Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer

Oncolytics Biotech® Reschedules Special Meeting of Shareholders to Change Jurisdiction of Incorporation to Nevada

Dec 9, 2025, 6:00 PM EST - 2 months ago

Oncolytics Biotech® Reschedules Special Meeting of Shareholders to Change Jurisdiction of Incorporation to Nevada

Oncolytics Biotech® Provides Update on Special Meeting of Shareholders

Nov 20, 2025, 4:05 PM EST - 2 months ago

Oncolytics Biotech® Provides Update on Special Meeting of Shareholders

Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer

Nov 19, 2025, 9:00 AM EST - 2 months ago

Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer

Oncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care

Oct 28, 2025, 7:30 AM EDT - 3 months ago

Oncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care

Oncolytics Biotech® Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada

Oct 20, 2025, 9:00 AM EDT - 3 months ago

Oncolytics Biotech® Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada

Oncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study

Sep 29, 2025, 8:30 AM EDT - 4 months ago

Oncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study

Oncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion

Sep 16, 2025, 7:00 AM EDT - 5 months ago

Oncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion

Oncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions

Sep 8, 2025, 7:00 AM EDT - 5 months ago

Oncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions

Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors

Sep 2, 2025, 9:10 AM EDT - 5 months ago

Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors

Oncolytics Biotech® Announces Upcoming Investor Conferences in September

Aug 28, 2025, 8:30 AM EDT - 5 months ago

Oncolytics Biotech® Announces Upcoming Investor Conferences in September

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

Aug 11, 2025, 4:55 PM EDT - 6 months ago

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep

Aug 8, 2025, 9:05 AM EDT - 6 months ago

Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep

Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange

Aug 8, 2025, 9:00 AM EDT - 6 months ago

Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange

Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results

Aug 5, 2025, 8:30 AM EDT - 6 months ago

Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results

Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End

Jul 29, 2025, 8:30 AM EDT - 6 months ago

Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End

Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential

Jul 23, 2025, 9:39 AM EDT - 6 months ago

Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential

Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules

Jul 22, 2025, 3:32 PM EDT - 7 months ago

Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules

Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types

Jul 16, 2025, 8:30 AM EDT - 7 months ago

Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types

Oncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers

Jul 10, 2025, 8:30 AM EDT - 7 months ago

Oncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers

Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies

Jul 8, 2025, 8:30 AM EDT - 7 months ago

Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies

Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy

Jun 30, 2025, 7:00 AM EDT - 7 months ago

Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy

Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs

Jun 11, 2025, 7:00 AM EDT - 8 months ago

Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs

Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities

May 23, 2025, 7:00 AM EDT - 9 months ago

Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities

Oncolytics Biotech Inc. (ONCY) Q1 2025 Earnings Call Transcript

May 14, 2025, 7:21 PM EDT - 9 months ago

Oncolytics Biotech Inc. (ONCY) Q1 2025 Earnings Call Transcript

Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum

May 14, 2025, 4:01 PM EDT - 9 months ago

Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

May 6, 2025, 7:00 AM EDT - 9 months ago

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action

Apr 24, 2025, 7:00 AM EDT - 10 months ago

Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action

Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital

Apr 10, 2025, 6:09 PM EDT - 10 months ago

Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital

Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers

Apr 10, 2025, 7:00 AM EDT - 10 months ago

Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers

Oncolytics Biotech Inc. (ONCY) Q4 2024 Earnings Call Transcript

Mar 7, 2025, 11:11 AM EST - 11 months ago

Oncolytics Biotech Inc. (ONCY) Q4 2024 Earnings Call Transcript

Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024

Mar 7, 2025, 7:00 AM EST - 11 months ago

Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

Feb 25, 2025, 7:00 AM EST - 1 year ago

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025

Feb 19, 2025, 7:00 AM EST - 1 year ago

Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025

Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer

Feb 18, 2025, 7:00 AM EST - 1 year ago

Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer

Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Feb 14, 2025, 5:15 PM EST - 1 year ago

Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Oncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence

Feb 7, 2025, 9:24 PM EST - 1 year ago

Oncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence

Oncolytics Biotech® to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium

Jan 22, 2025, 7:00 AM EST - 1 year ago

Oncolytics Biotech® to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium

Regulatory Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data

Jan 15, 2025, 7:02 AM EST - 1 year ago

Regulatory Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data

Oncolytics Biotech® Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data

Dec 23, 2024, 7:00 AM EST - 1 year ago

Oncolytics Biotech® Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data

Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium

Dec 18, 2024, 7:00 AM EST - 1 year ago

Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium

Oncolytics Biotech® Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial's New Pancreatic Cancer Cohort

Dec 3, 2024, 7:00 AM EST - 1 year ago

Oncolytics Biotech® Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial's New Pancreatic Cancer Cohort

Oncolytics Biotech Inc. (ONCY) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 9:01 PM EST - 1 year ago

Oncolytics Biotech Inc. (ONCY) Q3 2024 Earnings Call Transcript

Oncolytics Biotech® Reports Third Quarter 2024 Financial Results and Operational Highlights

Nov 12, 2024, 7:00 AM EST - 1 year ago

Oncolytics Biotech® Reports Third Quarter 2024 Financial Results and Operational Highlights

charlietwodogs
charlietwodogs Feb. 4 at 12:21 AM
$ONCY folks are pinning their hope on the move to nevada.. Best of luck...
0 · Reply
charlietwodogs
charlietwodogs Feb. 3 at 11:06 PM
$ONCY stupid AI BOT diamond
0 · Reply
De_man
De_man Feb. 3 at 10:31 PM
$ONCY Sp on does not matter to CF because he says it will not affect him even if the stock goes bust. On a positive not RVMD which tanked is trading at at mere 96.75 while oncy closed at .8778 , a couple decimal points off. and now we are worth once again less than 100 million but no worries as we are worth at least what the comparative stock is so we hone have to go up in value over 100 times where we are. This makes no sense except for maybe all those institutions that cf was so sure bought in maybe changed their mind and sold or no support. NO one knows what is going on but we will all keep our hopes up along with the stupid predictions. Although someone on the other board did predict a while ago, see you back at .90 and seems that they have a better track record than most. All good though, the redomicile and for sure patent extension and expected more results will all save the day....oh just one thing, we still need money.
0 · Reply
DiamondHandsHarold
DiamondHandsHarold Feb. 3 at 10:28 PM
$ONCY has real science behind it and the cancer space is starting to wake up again. Feels like one people circle back to.
0 · Reply
charlietwodogs
charlietwodogs Feb. 3 at 9:37 PM
$ONCY im sure glad price doesn't matter canadafan...
0 · Reply
charlietwodogs
charlietwodogs Feb. 3 at 9:33 PM
$ONCY where are the pumpers when we need them???🐓💩
0 · Reply
charlietwodogs
charlietwodogs Feb. 3 at 9:28 PM
$ONCY new 52 week low coming soon.
0 · Reply
aaron03
aaron03 Feb. 3 at 9:21 PM
$ONCY Clear manipulation at the end, however, I have zero confidence in Kelly as CEO. It's unfortunate. I had high hopes for him. But he's another Coffey/Thompson. Moving to Nevada doesn't do anything to the company. Getting a partnership does. And he hasn't delivered.
1 · Reply
Arrankar2099
Arrankar2099 Feb. 3 at 9:11 PM
$ONCY Notable??!
0 · Reply
AI1234
AI1234 Feb. 3 at 9:02 PM
$ONCY what a dump at the close. No manipulation here…Nothing to see here… Good grief!!! Get on with a business transaction….
0 · Reply
Myman2
Myman2 Feb. 3 at 9:01 PM
$ONCY What the F just happened??
0 · Reply
charlietwodogs
charlietwodogs Feb. 3 at 8:21 PM
$ONCY and ur point green??
0 · Reply
Greenkeeper11
Greenkeeper11 Feb. 3 at 8:01 PM
$ONCY A bit player😂
1 · Reply
charlietwodogs
charlietwodogs Feb. 3 at 7:17 PM
$ONCY stock will plummet to new 52 week low at that point.
0 · Reply
charlietwodogs
charlietwodogs Feb. 3 at 7:16 PM
$ONCY there will be news out soon... but it will not be good news for the investors 🐓🐓💩💩🥵
0 · Reply
Lenders
Lenders Feb. 3 at 7:04 PM
$ONCY Hitting the Atm and diluting our shares. Running out of money fast.
0 · Reply
charlietwodogs
charlietwodogs Feb. 3 at 7:00 PM
$ONCY this is only a day trading stock at best... who wants to tie up their money long term with this POS
0 · Reply
FoxM07
FoxM07 Feb. 3 at 6:52 PM
$ONCY in 7 months with Ambryx Jared was a bit player who helped engineer a $2B buyout by J&J. In 8 months with Oncy he hasn't accomplished much at all. The high pt of his tenure was recently getting this unwanted penny stock biotech to $1.30 only to have it plummet again. The market continues to price Oncolytics as an extreme risk that's likely heading for a costly financing. The 100k insider buy aside, it doesn't appear a partnership is imminent. GL.
0 · Reply
charlietwodogs
charlietwodogs Feb. 3 at 6:48 PM
$ONCY buying more at 35 cents...
0 · Reply
charlietwodogs
charlietwodogs Feb. 3 at 6:47 PM
$ONCY horrible leadership 💩💩
0 · Reply
charlietwodogs
charlietwodogs Feb. 3 at 6:07 PM
$ONCY pos
0 · Reply
CaseyLe
CaseyLe Feb. 3 at 3:34 PM
$ONCY if we do get an early buyout 2026-mid 2027, I’d think Johnson and Johnson would be it.
1 · Reply